Industry: Pharmaceuticals, Biotechnology
ARCA Discovery, Inc. is a privately held biopharmaceutical company developing genetically-targeted therapies for heart failure and other cardiovascular diseases. The Company closed a $15 million Series A financing in February, 2006 led by Atlas Venture, Boulder Ventures and Peqout Capital Management. The Company’s first product is bucindolol, a third generation beta-blocker-vasodilator for advanced heart failure and other indications, that promises to be the first genetically-targeted cardiovascular drug. Bucindolol has extensive Phase III data and a unique Phase III DNA sub-study. Using this sub-study, ARCA’s founding scientists have confirmed genetic polymorphisms that interact with bucindolol’s unique pharmacology to modify patient ( www.arcadiscovery.com )
ARCA Discovery , Inc.
1200 17Th Street Suite 620
Denver, Colorado 80202
USA
Tel: (303) 893-1599
Fax: (303) 825-0883